GoldenGolden
Sensei Biotherapeutics

Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage immunotherapy company that engages in the discovery and development of next generation therapies with a primary focus on the treatments for cancer.

Sensei Biotherapeutics is a clinical-stage immunotherapy company that engages in the discovery and development of next generation therapies with a primary focus on the treatments for cancer. Its proprietary ImmunoPhage™ platform is a self-adjuvanted and differentiated immunotherapy approach designed to use bacteriophage to induce a focused and coordinated innate and adaptive immune response.

The company is driven by scientists and an entrepreneurial culture that focus on rigorous science, innovative treatments, and data-driven decision making, it discovers and develops medicines that possess the potential to alter the treatment landscape and add value to patients and society. The company has developed a drug discovery approach, ImmunoPhage, that generates specific immune responses.

Its lead program, SNS-301, targets the tumor antigen, Aspartyl beta Hydroxylase (ASPH), and is in an ongoing Phase 1/2 trial in combination with pembrolizumab for the treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN). The company has more programs in several stages of preclinical development.

Timeline

January 2021
Sensei Biotherapeutics raises a $100,000,000 series E round from Steve Jurvetson and Uma Thurman.
May 27, 2020
Sensei Biotherapeutics completes acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 5, 2021
BioSpace
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointments of Maura Gillison, M.D., Ph.D., Professor of Medicine,
Amirah Al Idrus
February 4, 2021
FierceBiotech
Months after banking a $28.5 million venture round, Sensei Biotherapeutics is hitting Wall Street with a $133 million IPO. The proceeds will fund a trio of personalized cancer medicines into and through the clinic, including vaccines for a rare skin cancer and head and neck cancer as well as treatments designed to boost the immune response in the tumor microenvironment.
Ben Adams
June 15, 2020
FierceBiotech
It was just two years ago that immuno-oncology biotech Sensei hired a new chief medical officer; now, it's at it again, tapping Merus exec Marie-Louise Fjällskog, M.D., Ph.D., as it latest CMO.
BioSpace
May 27, 2020
BioSpace
Sensei Biotherapeutics , Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the acquisition of Alvaxa Biosciences, Inc., a camelid antibody therapeutics company with technology licensed from Fred Hutchinson Cance

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.